Literature DB >> 28490611

Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis.

Zeinab Ghorbanoghli1,2, Barbara Aj Bastiaansen3, Alexandra Mj Langers1, Fokko M Nagengast4, Jan-Werner Poley5, James Ch Hardwick1, Jan J Koornstra6, Silvia Sanduleanu7, Wouter H de Vos Tot Nederveen Cappel8, Ben Jm Witteman9, H Morreau10, Evelien Dekker3, Hans Fa Vasen1,2.   

Abstract

BACKGROUND: Screening of patients with familial adenomatous polyposis (FAP) have led to a substantial reduction in mortality due to colorectal cancer (CRC). Recent guidelines suggest that surveillance of non-intestinal malignancies should also be considered in those patients. However, the value of these surveillance programmes is unknown. The aims of this study were (1) to assess the occurrence of extracolonic malignancies in a large series of adenomatous polyposis coli (APC) mutation carriers and (2) to evaluate the causes of death.
METHODS: All APC mutation carriers were selected from the Dutch polyposis registry. Data on causes of death were collected. Pathology reports were retrieved from the Dutch Pathology Registry.
RESULTS: A total of 85 extracolonic malignancies were diagnosed in 74 of 582 APC mutation carriers. Duodenal and skin cancers were the most prevalent cancers. Thyroid cancer was observed in only 1.5% of the cases. The main cause of death was cancer (59% of all deaths), with 42% due to CRC and 21% due to duodenal cancer. One patient died from thyroid cancer. The second and third most common causes of death were cardiovascular disease (13% of all deaths) and desmoid tumours (11% of all deaths), respectively.
CONCLUSION: Extending surveillance programmes to other cancers will not contribute significantly to the survival of patients with FAP. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  APC mutation; Extracolonic cancer; FAP; Familial adenomatous polyposis

Mesh:

Year:  2017        PMID: 28490611     DOI: 10.1136/jmedgenet-2017-104545

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  3 in total

1.  Outcome of thyroid ultrasound screening in FAP patients with a normal baseline exam.

Authors:  Marc Monachese; Gautam Mankaney; Rocio Lopez; Margaret O'Malley; Lisa Laguardia; Matthew F Kalady; James Church; Joyce Shin; Carol A Burke
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

2.  Validation of the Endoscopic Part of the Spigelman Classification for Evaluating Duodenal Adenomatosis in Familial Adenomatous Polyposis: A Prospective Study of Interrater and Intrarater Reliability.

Authors:  John Gásdal Karstensen; Steffen Bülow; Johan Burisch; Mark Bremholm Ellebæk; Marcin Ostapiuk; Hans Christian Pommergaard; Palle Nordblad Schmidt
Journal:  Am J Gastroenterol       Date:  2022-02-01       Impact factor: 12.045

3.  Gastric adenomas and their management in familial adenomatous polyposis.

Authors:  Isabel Martin; Victorine H Roos; Chukwuemeka Anele; Sarah-Jane Walton; Victoria Cuthill; Noriko Suzuki; Barbara A Bastiaansen; Susan K Clark; Alexander von Roon; Evelien Dekker; Andrew Latchford
Journal:  Endoscopy       Date:  2020-11-05       Impact factor: 9.776

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.